LiquidGx_tm LiquidGx
A non-invasive cancer test that can easily become part of your workflow
LiquidGX_icon1_small LiquidGx
Established guidelines
recommend liquid biopsy
when tissue biopsy is not
feasible
LiquidGX_icon2_small LiquidGx
Utilizes proprietary
technology to analyze
ctDNA/RNA to accurately
detect cancer-driving
mutations
LiquidGX_icon3_small LiquidGx
Measures actionable
mutations from blood for
the selection of solid tumor
targeted treatment
LiquidGX_icon4_small LiquidGx
Testing at multiple time
points allows
quantitative monitoring
for drug resistance
markers
Clear, Color-Coded Results
Box_Full_new LiquidGx
Download_Sample_Report_Maroon_small LiquidGx
Liquid_Gx_table_group_small LiquidGx
  • Single gene analytes via qPCR that can be
    run individually or multiplexed
  • Offers accurate results within 3-5 business
    days so results can be in-hand before a
    patient’s first oncology consultation
  • Limit-of-detection 0.01%, the equivalent of
    finding one DNA fragment in 10,000
  • EGFR T790M and EGFR C797S variant detection
    for drug resistance monitoring included
LiquidGxLung_logo_table_group LiquidGx
  • Next Generation Sequencing test, coverage of >110
    variants in 10 genes frequently mutated in lung cancer
  • Turnaround time of 7-10 business days, which is
    faster than standard protocols including reflexive
    FISH and immunohistochemistry testing
  • Limit-of-detection 0.1%
  • Input includes both ctDNA and ctRNA allowing
    for optimal fusion detection including, novel fusions

LiquidGxLung™ quantifiably detects variants, producing actionable results

LiquidGxLung_table_group LiquidGx

LiquidGx™ complements Admera Health’s suite of molecular diagnostics:

pgxonco_box LiquidGx
OncoGxOne_box-1 LiquidGx
OncoGxSelect_box-1 LiquidGx